Navigation Links
Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX
Date:7/14/2009

HOBOKEN, N.J., July 15 /PRNewswire/ -- A recent study published in "International Immunopharmacology," reveals why Pycnogenol(R) (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, is effective for reducing inflammation and soothing pain associated with various health problems. Dr. Raffaella Canali of the National Research Institute on Food and Nutrition in Rome, Italy, found that Pycnogenol(R) inhibits the generation of COX-2 and 5-LOX, two naturally occurring enzymes associated with a host of inflammatory conditions.

"This study reveals that Pycnogenol can actually decrease pain and reduce inflammatory conditions, as has been previously reported, by shutting down the production of specific enzymes involved with inflammation," said Dr. Canali.

Inflammation is a tightly controlled, concerted action of immune cells fighting infections, irritations and injuries. When inflammation goes out of control it may target the body's own tissue such as in arthritis or asthma. The worst known cases are the auto-immune diseases.

The study investigated healthy volunteers ranging from ages 35-50, who consumed Pycnogenol(R) tablets (150 mg) for five consecutive days in the morning before breakfast. Blood was drawn before and after supplementation to investigate how immune cells respond towards pro-inflammatory stimuli. The behavior of specific white blood cells (leukocytes) for generating a repertoire of enzymes in inflammatory condition was tested by real-time PCR. The gene expression of enzymes COX-2, 5-LOX, FLAP and COX-1 were monitored and the products these enzymes generate, prostaglandins and leukotrienes, were quantified.

A baseline study revealed that the volunteers' immune cells rapidly initiated production of COX-2, 5-LOX and FLAP enzymes upon pro-inflammatory stimulation. Taking Pycnogenol(R) almost entirely subdued COX-2, 5-LOX and FLAP induction in the immune cells of volunteers. Control studies showed that Pycnogenol(R) did not have an effect on generation of the COX-1 enzyme, thus the potential for typical NSAID side effects is defied. While Pycnogenol(R) is not a COX-2-specific inhibitor; it blocks the COX-2 enzyme production during inflammation only. There are COX-2 enzymes not involved in inflammation in other organs such as the kidneys, where it has important physiologic functions.

"Standard NSAID medications reduce the production of prostaglandins by COX enzymes for lowering the pain," explains Dr. Canali. "In contrast, Pycnogenol(R) turns to the root of the problem, completely stopping the production of COX-2 in inflammation. Thus far, Pycnogenol(R) seems to be a unique tool for modulating inflammatory processes."

These pharmacologic findings are consistent with past clinical trials of Pycnogenol(R) that showed significantly lowered leukotriene levels in asthmatic patients, a condition originating from 5-LOX. Three recent clinical trials also showed pain relief and a reduced need for pain medication in arthritis patients after taking Pycnogenol(R), results that are linked to COX-2 inhibition. One arthritis study showed a significant reduction of inflammatory marker C-reactive protein. Pycnogenol(R) has been shown to inhibit inflammation in several dysmenorrhoea studies and also a reduction in skin inflammation related to sunburn and acne.

About Pycnogenol(R)

Pycnogenol(R) is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 40 years and has more than 220 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol(R) is available in more than 700 dietary supplements, multi-vitamins and health products worldwide. For more information, visit www.pycnogenol.com.

Natural Health Science Inc. (NHS), based in Hoboken, New Jersey, is the North American distributor for Pycnogenol(R) (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research. Pycnogenol(R) is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #5,720,956 / #6,372,266 and other international patents. Horphag Research Ltd. is the recipient of the 2008 Frost & Sullivan North American Health Ingredients Excellence in Research Award. NHS has the exclusive rights to market and sell Pycnogenol(R) in North America and benefits from more than 40 years of scientific research assuring the safety and efficacy of Pycnogenol(R) as a dietary supplement. For more information about Pycnogenol(R) visit our Web site at www.pycnogenol.com.


'/>"/>
SOURCE Natural Health Science Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Study finds survival rates from gastrointestinal tumors improving among African-Americans
2. Mayo Clinic study continues to refine most effective methods to predict Alzheimers disease
3. Mayo Clinic Study Continues to Refine Most Effective Methods to Predict Alzheimers Disease
4. Reminder program dramatically increases mammography rates, Kaiser Permanente study finds
5. FAIR CEO Blasts Kaiser Foundation & Public Agenda HIV/AIDS Study Results as "Absolute Nonsense"
6. Reminder Program Dramatically Increases Mammography Rates, Kaiser Permanente Study Finds
7. Study estimates radiation dose, cancer risk from coronary artery calcium screening
8. Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows
9. Queens University study aims at early diagnosis for ADHD and Parkinsons disease
10. Cats Purrfect at Getting Needs Met, Study Shows
11. Study Evaluating Efficacy and Safety of Two Low-dose Regimens of PREMARIN Vaginal Cream for the Treatment of Moderate to Severe Vaginal Atrophy Now Published
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss ... WE TV’s “Mama June: From Not to Hot,” which will begin airing on February ... Shannon, known to millions from the 2012 reality television series, “Here Comes Honey Boo ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Dr. David ... in Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated ... is an online directory that recognizes local physicians and dentists who have earned ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for ... Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory ... disorder (ASD) to see films in an environment that accommodates their unique needs. ...
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for ... expert sit stand solutions representative to the Minneapolis Home and Garden Show which is ... event that is garnering national attention is the Minneapolis Convention Center. , From ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based company ... announced its products are coming soon to Amazon.com, the world’s largest online retailer. ... a means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device ... for the urology market, will release financial results for ... 2016 before the market open on Thursday, March 9, ... conference call and webcast to discuss its financial results ... 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , February 23, 2017 ... Market by Product (X-ray Imaging Digital, Analog), MRI (Closed, ... (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) ... report studies the global market over the forecast period ... reach ~USD 36.43 Billion by 2021, at a CAGR ...
Breaking Medicine Technology: